jev
singlemost
import
caus
viral
enceph
asia
case
fatal
rate
averag
jev
major
problem
southeast
asia
india
china
viru
endem
recent
year
jev
spread
geograph
area
australia
pakistan
thu
becom
import
emerg
viru
infect
area
vaccin
jev
use
mous
brainderiv
inactiv
vaccin
shown
effect
led
decreas
diseas
burden
howev
concern
immunogen
safeti
vaccin
liveattenu
strain
cell
culturebas
see
front
matter
elsevi
ltd
right
reserv
jev
vaccin
produc
primari
hamster
kidney
phk
cell
licens
use
china
shown
safe
effect
howev
sinc
phk
approv
cell
line
product
human
vaccin
mani
countri
use
jev
vaccin
therefor
recombin
proteinbas
vaccin
repres
attract
altern
e
protein
flavivirus
immunogen
suitabl
purpos
vaccin
develop
protein
e
consist
three
structur
domain
didiii
diii
contain
predominantli
subcomplexand
typespecif
epitop
mani
induc
neutral
antibodi
sever
vaccin
base
diii
shown
immunogen
effect
certain
condit
nucleotid
e
protein
access
passag
obtain
health
protect
agenc
porton
uk
constitut
ectodomain
diii
caggatccaggaacaacctatggcgtct
atgtcgactttgccaatgctgcttcca
clone
bacteri
vector
invitrogen
upstream
histidin
repeat
string
recombin
diii
rdiii
protein
express
induc
purif
rdiii
perform
nickelaffin
chromatographi
previous
describ
purif
solubilis
rdiii
result
pure
fraction
rdiii
shown
use
subsequ
vaccin
experi
authent
purifi
recombin
wnv
e
diii
protein
confirm
western
blot
analys
use
wnv
monoclon
antibodi
bioreli
corp
rockvil
usa
rdiii
protein
molecular
weight
kda
correspond
describ
previous
produc
inactiv
whole
viru
vaccin
wnv
propag
vero
cell
concentr
purifi
sucros
gradient
centrifug
subsequ
inactiv
bpl
biosafetylevel
laboratori
use
method
previous
describ
inactiv
sar
coronaviru
vaccin
prepar
use
primari
immun
adjuv
synthet
cpg
oligonucleotid
odn
tccatgacgttcctgacgtt
sigma
haverhil
uk
mous
optim
booster
immun
vaccin
candid
adjuv
oil
stimun
cedidiagnost
lelystad
netherland
recommend
manufactur
immun
experi
perform
follow
six
group
mice
immun
subcutan
g
purifi
rdiii
group
b
g
bplinactiv
wnv
wnvbpl
group
c
control
vaccin
g
bplinactiv
rabi
group
e
f
anim
immun
first
g
odn
adjuv
vaccin
day
boost
oiladjuv
vaccin
day
determin
virusspecif
igg
respons
upon
vaccin
enzymelink
immunosorb
assay
elisa
develop
use
strain
antigen
end
purifi
viru
solubilis
endconcentr
gml
pb
contain
wv
sigma
zwiijndrecht
netherland
microtitr
plate
costar
cambridg
usa
coat
g
total
protein
dilut
pb
per
well
twofold
dilut
sera
prepar
pb
contain
wv
bovin
serum
albumin
wv
dri
milk
powder
wv
sodium
chlorid
sigma
zwijndrecht
netherland
viru
specif
igg
measur
use
hrpo
label
goatantimous
dako
glostrup
denmark
titer
express
reciproc
highest
serum
dilut
od
nm
valu
higher
three
time
background
od
nm
valu
titer
consid
neg
base
cutoff
valu
establish
sera
mice
toward
wnv
jev
primari
vaccin
mice
group
ab
develop
low
igg
antibodi
titer
wnv
titer
jev
wherea
anim
group
cd
develop
igg
antibodi
titer
rang
wnv
antibodi
titer
jev
worth
realiz
week
postprimari
vaccin
mainli
low
affin
antibodi
produc
could
explain
crossreact
antibodi
measur
jev
booster
vaccin
igg
titer
wnv
increas
group
ab
group
cd
titer
jev
increas
group
ab
group
cd
none
mockvaccin
anim
develop
specif
antibodi
titer
determin
viru
neutral
vn
antibodi
titer
serial
twofold
dilut
heatinactiv
mous
sera
incub
tcid
wnv
jev
vn
titer
express
reciproc
highest
serum
dilut
still
give
suppress
cytopath
effect
primari
immun
low
vn
titer
measur
wnv
vaccin
mice
fig
vn
titer
measur
jev
fig
booster
anim
develop
high
vn
titer
wnv
crossneutr
antibodi
titer
measur
jev
fig
lower
homolog
viru
fig
method
use
solubil
rdiii
inclus
bodi
prior
purif
renatur
critic
step
sinc
correct
fold
diii
determin
format
neutral
epitop
observ
mice
vaccin
rdiii
develop
neutral
antibodi
homolog
wnv
heterolog
jev
indic
use
procedur
least
portion
solubilis
rdiii
fold
correctli
howev
target
experi
need
prove
renatur
success
determin
percentag
solubilis
protein
fold
correctli
day
anim
group
c
e
challeng
intraperiton
lethal
dose
tcid
anim
group
b
f
challeng
intraperiton
lethal
dose
tcid
mockvaccin
mice
e
f
show
bodi
weight
loss
fig
die
within
day
pi
irrespect
viru
use
challeng
infect
fig
mice
vaccin
rdiii
challeng
wnv
jev
b
protect
weight
loss
degre
compar
wnvbpl
vaccin
anim
fig
indic
rdiii
provid
signific
protect
mice
develop
weight
loss
surviv
rate
five
anim
group
also
monitor
lethal
challeng
wnv
jev
fig
surviv
rate
observ
group
b
respect
wherea
rate
seen
group
c
differ
surviv
curv
group
analyz
logrank
test
incorpor
graphpad
prism
version
softwar
graphpad
softwar
san
diego
usa
test
use
complet
survivalcurv
compar
group
valu
p
consid
statist
signific
differ
group
e
group
c
e
statist
signific
p
p
respect
similarli
signific
differ
measur
group
b
f
group
f
p
respect
group
c
compar
signific
differ
surviv
rate
observ
p
indic
efficaci
rdiiibas
vaccin
similar
wnvbpl
vaccin
protect
mice
lethal
wnv
challeng
five
mice
group
sacrif
day
pi
timepoint
first
sign
paralysi
appear
mockvaccin
anim
brain
collect
viru
titrat
high
wnv
averag
tcid
g
brain
jev
averag
tcid
g
brain
titer
detect
brain
group
e
f
respect
fig
one
five
mice
group
detect
wnv
tcid
g
brain
two
five
figur
viru
titer
brain
mice
challeng
wnv
jev
vaccin
mice
challeng
intraperiton
tcid
b
tcid
day
pi
five
mice
sacrif
brain
tissu
collect
viru
titer
determin
vero
cell
mean
viru
titer
per
group
calcul
error
bar
indic
standard
deviat
anim
group
b
detect
jev
brain
respect
diii
protein
highli
conserv
sever
wnv
strain
wnv
strain
use
studi
share
overal
amino
acid
ident
similar
valu
strain
respect
explain
level
protect
lethal
wnv
jev
infect
seen
mice
diii
function
receptorbind
domain
form
continu
polypeptid
segment
fold
independ
certain
mutat
within
diii
shown
affect
virul
tropism
flavivirus
rdiii
stabl
protein
therefor
attract
candid
use
subunit
vaccin
lack
glycosyl
protein
express
prokaryot
cell
like
affect
antigen
sinc
nativ
diii
glycosyl
well
recombin
diii
jev
dengu
viru
shown
immunogen
protect
mice
challeng
respect
virul
virus
underlin
suitabl
diiibas
vaccin
formul
flavivirus
surviv
result
consist
recent
studi
show
efficaci
diii
protect
balbc
mice
intracerebr
challeng
wnv
jev
studi
howev
mice
vaccin
g
rdiii
adjuv
cpg
rel
high
concentr
rdiii
need
induct
neutral
antibodi
respons
may
indic
rdiii
poorli
immunogen
experi
need
determin
percentag
solubilis
protein
fold
correctli
purif
procedur
use
studi
may
affect
immunogen
rdiii
collect
result
obtain
present
studi
indic
diii
promis
welldefin
vaccin
candid
combin
good
adjuv
use
induct
protect
immun
wnv
jev
although
wnvbpl
vaccin
immunogen
result
better
protect
diiibas
vaccin
result
statist
better
result
indic
similar
efficaci
two
vaccin
formul
wnv
therefor
evalu
diiibas
vaccin
mammalian
speci
includ
human
seem
warrant
